PHILADELPHIA, PA and REHOVOT, ISRAEL--(Marketwire - Sep 20, 2012) - Rosetta Genomics Ltd. (
The Company's presentation will be posted to its website at www.rosettagenomics.com.
About Aegis Capital
Founded in 1984, Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital's management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of our clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. Aegis Capital continues to meet the challenging and changing markets by investing in world-class services such as access to independent research for its financial advisors and their clients from JP Morgan, Bloomberg, Moody's, Lipper, Best Independent Research LLC, and Argus Research. Aegis Capital's clients have access to Asset Management Services with world-class managers.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000 Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Rosetta's miRview® product line, as well as Rosetta's patent position, platform technologies and the application or commercialization of these, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
- Rosetta Genomics